News
2025/10/29
As reported by OncLive®, October 2025: FDA Grants Fast Track Designation to NBM-BMX for Metastatic Uveal Melanoma
TAIPEI and San Diego, USA – NovelWise Pharmaceutical Corporation today announced that its investigational agent NBM-BMX, a selective HDAC8 inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic uveal melanoma, a rare and aggressive eye cancer with limited therapeutic options.
2025/08/25
Novelwise Pharmaceuticals Announces Collaboration with U.S. Patient Advocacy Group A Cure In Sight (ACIS) to Advance Ocular Melanoma Research
Novelwise Pharmaceuticals is honored to announce its collaboration with the U.S. patient advocacy organization A Cure In Sight (ACIS) in August 2025.
2025/07/30
Novelwise Pharmaceuticals Announces FDA“May Proceed”Clearance for Phase Ib/II Trial of NBM-BMX in Metastatic Uveal Melanoma
Taipei, July 30, 2025 —— Novelwise Pharmaceuticals today announced that its investigational cancer therapy NBM-BMX has been deemed may proceed by the United States Food and Drug Administration (US FDA).